Crizotinib may be effective again after chemo

Updated: Feb 15

Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC.


This case is a proof of concept that re-challenging with crizotinib after intervening chemotherapy is feasible in ROS1-rearranged NSCLC with acquired resistance.


Read full article here.

1 view0 comments

Recent Posts

See All